Ligand Pharmaceuticals vs RadNet
Ligand Pharmaceuticals (LGND), health care, and RadNet (RDNT), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Ligand Pharmaceuticals and RadNet are valued at about the same: $5.9B and $5.9B. Ligand Pharmaceuticals's operating margin in its latest fiscal year was 15.3% and RadNet's 3.04%. Over the past year Ligand Pharmaceuticals's share price has moved +45.7% and RadNet's -2.87%.
Key facts
- Ligand Pharmaceuticals market value
- $5.9B
- RadNet market value
- $5.9B
- Ligand Pharmaceuticals P/E
- 121
- Ligand Pharmaceuticals revenue
- $268.1MFY to 2025-12-31
- RadNet revenue
- $2BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Ligand Pharmaceuticals | RadNet |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $5.9Blower | $5.9Bhigher |
| Revenue | $268.1Mlower | $2Bhigher |
| Earnings | $124.5Mhigher | -$18.7Mlower |
| Employees | 47lower | 12,000higher |
| Total assets | $1.6Blower | $3.8Bhigher |
| Valuation | ||
| P/E | 121 | — |
| P/S | 21.9higher | 2.9lower |
| P/B | 6.1higher | 5.3lower |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | 15.3%higher | 3.04%lower |
| Balance sheet | ||
| Net assets | $1Blower | $1.1Bhigher |
| Total liabilities | $543.4Mlower | $2.4Bhigher |
| Total debt | — | $1.1B |
| Cash on hand | $174.9Mlower | $767.2Mhigher |
| Price change | ||
| Today | -2.62%lower | -2.56%higher |
| 1 year | +45.7%higher | -2.87%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Ligand Pharmaceuticals only (0)
None of the tracked investors.
RadNet only (3)
- Ron Baron0.1%
- Mairs & Power team0.1%
- Temasek<0.1%
Percentages are each holding's share of that investor's reported portfolio. · Who owns RDNT
More on Ligand Pharmaceuticals
Further comparisons
Ligand Pharmaceuticals against its closest peers
RadNet against its closest peers
Learn
Questions and answers
Which is bigger, Ligand Pharmaceuticals or RadNet?
By market value, RadNet is the larger: $5.9B against $5.9B for Ligand Pharmaceuticals. By revenue in its latest fiscal year, RadNet is the larger: $2B against $268.1M for Ligand Pharmaceuticals.
Which has the higher operating margin?
Ligand Pharmaceuticals: 15.3%, against 3.04% for RadNet. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Ligand Pharmaceuticals and RadNet?
None of the tracked superinvestors holds both in their latest 13F filing. 0 hold Ligand Pharmaceuticals and 3 hold RadNet.
Cite this page
Funkfolio, “Ligand Pharmaceuticals vs RadNet”, data as of 18 November 2026. https://funkfolio.com/compare/lgnd-vs-rdnt
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.